FIELD: medicine; therapy.
SUBSTANCE: invention relates to medicine, namely to therapy; it can be used for prevention of interstitial pneumonia of infectious etiology. The method includes inhalation administration of low-molecular chitosan with molecular weight of less than 50 KDa in the form of an aqueous solution with a concentration of 0.2-1.4 wt.%.
EFFECT: use of the invention allows for achievement of reduction in the severity of pathomorphological changes in lung tissue, characteristic for interstitial pneumonia.
1 cl, 8 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MEANS FOR PREVENTION OF INTERSTITIAL PNEUMONIA | 2020 |
|
RU2747550C1 |
| STABLE AQUEOUS PHARMACEUTICAL COMPOSITION FOR INHALATIONS CONTAINING A HEXAPEPTIDE | 2020 |
|
RU2739573C1 |
| INHALED HEXAPEPTIDE FOR TREATING RESPIRATORY DISEASES ASSOCIATED WITH INTERLEUKIN-6 | 2020 |
|
RU2737799C1 |
| USE OF DALARGIN FOR PRODUCTION OF DRUG PREPARATIONS FOR PREVENTING PNEUMONIA | 2020 |
|
RU2728938C1 |
| METHOD FOR TREATMENT OF LUNG DISEASES BY INHALATION ADMINISTRATION OF MESENCHYMAL STROMAL CELLS AND HEXAPEPTIDE | 2022 |
|
RU2770364C1 |
| METHOD OF TREATING ACUTE RESPIRATORY DISTRESS SYNDROME BY DALARGIN AND A PULMONARY SURFACTANT | 2020 |
|
RU2728821C1 |
| USING DALARGIN FOR PRODUCING AGENTS FOR TREATING COVID-19 CORONAVIRUS INFECTION | 2020 |
|
RU2728939C1 |
| APPLICATION OF AN ALPHA1-PROTEINASE INHIBITOR (ALPHA1-ANTITRYPSIN) FOR PREVENTION AND/OR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND METHOD FOR PREVENTION AND/OR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME USING ALPHA1-ANTITRYPSIN | 2020 |
|
RU2757875C1 |
| USE OF HEXAPEPTIDE TO REDUCE LEVELS OF EXTRACELLULAR HMGB1 PROTEIN IN INFLAMMATORY DISEASES | 2021 |
|
RU2813878C2 |
| BIOMEDICAL CELL PRODUCT BASED ON MAMMALIAN MESENCHYMAL STROMAL CELLS AND HEXAPEPTIDE | 2022 |
|
RU2781968C1 |
